The 2026 Healthtech Messaging Index
Holmusk
holmusk.com·scored August 23, 2026
20/38
Invisible
The page is doing some work, but the story isn't landing fast enough. Buyers and AI are both left guessing what makes Holmusk different.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for Real-world evidence (RWE) data and analytics platform for neuropsychiatry and behavioral health, it named:
Buyer we put in the prompt: Head of Real-World Evidence, Medical Affairs Director, or HEOR Lead at a pharmaceutical or biotech company developing neuropsychiatry treatments. Both the buyer and the category were inferred from Holmusk’s homepage alone. The model had no web access.
Holmusk was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI named you when asked who it recommends for "Real-world evidence (RWE) data and analytics platform for neuropsychiatry and behavioral health", and described you accurately: "Holmusk is a health technology company specializing in real-world evidence for behavioral health and neuropsychiatry, known for their NeuroBlu database of psychiatric patient records used by pharma and payers.". Your positioning is landing with the machines.
Overall assessment
Holmusk's biggest strength is its data specificity ... 46.5M patients, 50-state coverage, condition-level breakdowns, and a named proprietary platform (NeuroBlu) give it genuine distinctiveness that AI engines can attribute uniquely to this company. The biggest gap is the complete absence of social proof and cost-of-inaction messaging: there are no customer logos, named testimonials, or case studies anywhere, and the page never tells a buyer what they risk by staying with the status quo, which kills urgency and trust for any skeptical pharma buyer.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
07Cost of Inaction
“No mention of failed drug trials, regulatory rejection, lost market access, or cost of staying without standardized data anywhere on the page.”
The page never names what a buyer loses, risks, or wastes by not acting ... no stakes, no urgency, no cost of inaction articulated.
All 19 signals, scored 0 to 2.
Total 20/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“Creating the standard for neuropsychiatry with best-in-class real-world evidence”
The vertical (neuropsychiatry) and broad mission are clear in 7 seconds, but who specifically this is for (researchers, pharma, payers?) and the precise problem solved are not instantly obvious without reading the body copy.
- 1
02Rebellion / Movement
“There is currently no standardized way to measure symptoms or quality of care for neuropsychiatric conditions”
A named status quo problem exists but there is no named enemy, no named industry pattern being rebelled against, and no missionary point of view beyond 'we'll fix the gap.'
- 2
03Owned Language & Category
“NeuroBlu Database" and "first-in-kind natural language processing models developed specifically for behavioral health”
Holmusk owns the named product term 'NeuroBlu' (Data and Analytics), coins 'first-in-kind NLP models for behavioral health,' and claims to be creating a new standard ... language an AI could specifically attribute to them.
- 1
04ICP Clarity
“Whether you're a researcher, a clinician, or a payer, we have a data-driven solution for your challenges.”
Three buyer personas are named but not prioritized, and company size, stage, or geography of the ideal buyer is never specified, making it hard for any one visitor to feel they are the clear target.
- 1
05Problem Leadership
“Neuropsychiatry needs better evidence to drive decision-making. There is currently no standardized way to measure symptoms or quality of care”
The page does open with a field-level problem statement before the solution, but it is framed in abstract clinical terms rather than in the buyer's operational language (e.g., failed trials, slow approvals, rejected formularies).
- 1
06Solution Clarity
“We've built the field's largest, most robust source of clinical data for real-world data and a uniquely powerful evidence engine.”
A visitor can roughly understand it's a real-world data and analytics platform for neuropsychiatry, but 'evidence engine' is vague and the sentence itself is grammatically awkward, reducing repeatability.
- 0
07Cost of Inactionweakest
“No mention of failed drug trials, regulatory rejection, lost market access, or cost of staying without standardized data anywhere on the page.”
The page never names what a buyer loses, risks, or wastes by not acting ... no stakes, no urgency, no cost of inaction articulated.
- 1
08Promised Land
“unlocking new and much-needed evidence to guide decisions for successful treatment development, efficient care delivery, and improved patient outcomes”
A vague after-state is described but it is generic ('successful treatment development,' 'improved outcomes') with no concrete, specific picture of what a researcher's or pharma team's day looks like after using NeuroBlu.
Trust Signal
4 signals
- 2
09Proof & Evidence
“46,500,000 Patients" "50 State coverage" "20+ Years of longitudinal data" "12.6M patients" for major depressive disorder”
The page is dense with specific, concrete numbers across conditions, geographies, and data scope ... well above adjective-only claims, though outcome deltas for customers are absent.
- 0
10Social Proof
“No customer logos, named testimonials, named case studies, or video stories anywhere in the scraped content.”
There is zero social proof in any form ... no named clients, no quotes with attribution, no logos ... despite serving pharma, providers, payers, and government.
- 1
11Authority & Credibility
“our team of clinical and data science experts" and "first-in-kind natural language processing models developed specifically for behavioral health”
Expertise is asserted through product claims and team mentions but no founder credentials, named researchers, published studies, awards, or original research reports are surfaced on the homepage.
- 0
12Alternatives Acknowledged
“No mention of competitors, alternative approaches (e.g., claims data, RCTs, synthetic data), or 'do nothing' scenario anywhere on the page.”
The page completely ignores buyer alternatives, making it impossible for a skeptical buyer to understand why NeuroBlu beats their current approach.
AI Signal
6 signals
- 1
13Customer Focus
“Whether you're a researcher, a clinician, or a payer, we have a data-driven solution for your challenges.”
The page mixes company capability storytelling with occasional buyer-role nods, but the majority of content describes Holmusk's assets and features rather than the customer's transformation journey.
- 2
14AI-Parmesan Index
“first-in-kind natural language processing models developed specifically for behavioral health”
AI/NLP use is described mechanistically and tied to a specific purpose (extracting unstructured clinical notes for neuropsychiatry), not sprinkled as a buzzword ... this earns full credit.
- 1
15LLM Quotability
“The NeuroBlu Database enables researchers to build robust patient cohorts and conduct studies at an unprecedented level of granularity.”
There are a few clean declarative sentences, but most are hedged, compound, or feature-listy ... an LLM could quote NeuroBlu's scale stats but would struggle to find a single crisp recommendation-ready sentence about outcomes.
- 0
16Copyright Freshness
“No visible blog post dates, case study dates, or copyright year present in the scraped content.”
No recency signals whatsoever are visible in the scraped homepage content, which is a direct negative for AI engine weighting.
- 2
17Entity Distinctiveness
“field's largest, most robust source of clinical data" + "NeuroBlu" + "first-in-kind NLP models developed specifically for behavioral health”
The named product (NeuroBlu), the specific vertical (neuropsychiatry/behavioral health), the scale claims, and the NLP-for-psychiatry angle combine to make Holmusk distinctly attributable ... an AI would not confuse this with IQVIA or Optum.
- 2
18AI Recommendation Check
“AI described you as: "Holmusk is a health technology company specializing in real-world evidence for behavioral health and neuropsychiatry, known for their NeuroBlu database of psychiatric patient records used by pharma and payers.”
AI named you when asked who it recommends for "Real-world evidence (RWE) data and analytics platform for neuropsychiatry and behavioral health", and described you accurately: "Holmusk is a health technology company specializing in real-world evidence for behavioral health and neuropsychiatry, known for their NeuroBlu database of psychiatric patient records used by pharma and payers.". Your positioning is landing with the machines.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“GET STARTED" and "Contact us" and "Request A Demo" and "LEARN MORE" appear across the page.”
There is a primary CTA and a soft secondary, but no numbered onboarding path or clear process is shown, and the CTAs are scattered with inconsistent labels, diluting conversion clarity.
Keep the lead
AI already names Holmusk. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Holmusk the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.